Cell therapy weekly: Kymriah™ shows long-lasting remissions in non-Hodgkin lymphomas

This week: a clinical trial has revealed that a significant number of non-Hodgkin lymphoma patients continue to be in remission 5 years after receiving a CAR-T therapy called Kymriah™, Cytiva and Brooks Life Sciences work together to enhance automation in cold chain solutions, Charles River will acquire Cognate BioServices to expand cell and gene therapy programs, and Cytovia Therapeutics has partnered with Cellectis to develop TALEN® gene-edited iPSC-derived NK and CAR-NK cells. The news highlights: Kymriah™ shows long-lasting remissions in non-Hodgkin lymphomas Cytiva and Brooks Life Sciences work together to enhance automation in cold chain solutions Charles River to acquire...